Healthcare insider activity showed $755.3 million in June transactions across biotech and digital health stocks.
Insider Trading
July 1, 2026
Table of Contents
June 30, 2026
A cluster of insider and major-holder transactions appeared across the healthcare and biotech sector in June, with filings showing approximately $755.3 million in reported activity across Spyre Therapeutics, Kymera Therapeutics, Kardigan, Enliven Therapeutics, Hinge Health, Oscar Health, and CG Oncology.
The headline number leaned heavily toward selling. Reported sales accounted for approximately $660.5 million, while purchases totaled about $94.8 million.
But the signal was more nuanced than a simple insider-selling story.
Most of the largest transactions came from venture funds, healthcare investment firms, 10% owners, or other institutional holders rather than operating executives. That makes the cleaner read a sector-wide monetization pattern, with several large backers reducing exposure after clinical, IPO, or stock-price momentum.
The largest transaction came from Spyre Therapeutics, Inc. (NASDAQ: SYRE), where Fairmount Funds Management sold approximately $399.7 million worth of stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) also saw a large fund-linked sale, with BVF Partners selling approximately $168.1 million worth of shares.
Enliven Therapeutics, Inc. (NASDAQ: ELVN) added another institutional sale, with OrbiMed selling approximately $39.0 million worth of stock.
Together, those three biotech names accounted for the majority of the reported selling in the group.
Spyre was the largest trade in the sample by a wide margin.
Fairmount’s reported sale represented more than half of the healthcare and biotech total. That makes it the headline transaction in the cluster.
Still, the filing should be framed carefully. This was a large-holder monetization event, not a direct management sale.
Spyre is a clinical-stage biotech focused on inflammatory bowel disease, and the company had positive clinical momentum in 2026. That context matters because large fund sales after strong clinical or stock momentum can reflect profit-taking, portfolio management, or fund liquidity rather than a negative read on the company’s pipeline.
Kymera was the second-largest healthcare and biotech trade in the sample.
BVF Partners’ reported sale accounted for more than one-fifth of the sector total. Kymera had also been trading around strong clinical interest tied to KT-621, its oral STAT6 degrader for inflammatory diseases.
That makes the transaction look more like fund monetization into strength than a simple bearish signal.
Enliven followed a similar pattern. OrbiMed’s $39.0 million sale was another large healthcare fund transaction, not an operating-executive sale. The cleaner read is sponsor liquidity rather than an internal company warning.
The cluster was not entirely bearish.
Kardigan, Inc. (NASDAQ: KARD) stood out as the largest buy-side name in the group, with HRTG GPE purchasing approximately $50.0 million worth of stock and ARCH Venture Partners tied to another $20.0 million purchase.
Combined, Kardigan accounted for about $70.0 million in reported insider and institutional buying.
The timing matters because Kardigan went public in June 2026. That makes the purchases more likely tied to IPO participation or offering structure rather than classic open-market insider buying. Even so, the size still points to meaningful institutional backing.
CG Oncology, Inc. (NASDAQ: CGON) also stood out because Brian Guan-Chyun Liu reported a purchase of approximately $24.8 million.
That was one of the stronger bullish signals in the group because it was a purchase, not a sale. In biotech, large insider buying can carry more interpretive weight because insiders and major holders understand the sector’s trial risk, financing needs, and regulatory timelines.
Hinge Health, Inc. (NYSE: HNGE) added a health-tech angle to the cluster.
Insight Holdings reported approximately $27.8 million in Hinge stock sales. Unlike the biotech pipeline names, Hinge is a digital health company focused on musculoskeletal care, so this filing is better read as post-IPO investor liquidity.
Oscar Health, Inc. (NYSE: OSCR) also appeared in the group, with Mario Schlosser selling approximately $25.9 million worth of stock.
That sale deserves more attention than some larger fund transactions because it involved an individual founder-linked insider rather than a venture fund or institutional holder.
The healthcare and biotech cluster looks bearish at first because the majority of the dollar value came from selling.
But the deeper signal is more specific.
This was mostly a sponsor, fund, and large-holder liquidity pattern across biotech and health-tech companies. It was not mainly a wave of CEOs and CFOs selling stock.
That distinction matters. Fund sales can reflect portfolio rebalancing, lockup-related liquidity, profit-taking after stock strength, fund lifecycle decisions, or ownership concentration management.
At the same time, the buy-side entries at Kardigan and CG Oncology show that investors were still willing to commit capital to selected clinical-stage and late-stage healthcare stories.
A single insider filing can be easy to misread. A sector cluster is more useful because it shows whether activity is isolated or part of a broader pattern.
In June, the healthcare and biotech pattern was clear: large holders monetized major positions, while a smaller group of buyers continued backing selected drug developers.
Platforms like LevelFields aggregate insider transactions and flag when activity exceeds key thresholds, helping investors identify when isolated filings become part of a larger ownership trend.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE